Anhui Anke Biotechnology (Group) Co., Ltd. Class A

Anhui Anke Biotechnology (Group) Co., Ltd. Class A

SSZSE:300009
7.63
CNY
-0.07
(-0.91%)
0.40EPS
22.09P/E
14.38BMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.31
0.39
0.44
0.56
0.71
0.93
1.03
1.04
1.36
1.43
1.73
1.51
1.58
1.4
Basic EPS, GAAP
0.06
0.08
0.1
0.13
0.18
0.17
0.08
0.22
0.13
0.43
0.51
0.42
0.44
0.39
Free Cash Flow per Basic Share
0.02
0.01
0.06
0.12
0.1
0.05
0.07
0.2
0.29
0.14
0.46
0.34
0.44
- -
Dividend per Share
0.03
0.03
0.03
0.04
0.05
0.07
0.1
0.1
0.17
0.2
0.25
0.25
0.25
0.26
Book Value per Share
0.47
0.53
0.81
0.87
1.08
1.23
1.6
1.73
1.7
1.92
2.23
2.47
2.73
2.62
Tangible Book Value per Share
0.46
0.45
0.53
0.36
0.57
0.68
1.12
1.21
1.36
1.48
1.79
2.06
2.33
2.22
Basic Weighted Avg Shares
1,391
1,398
1,433
1,529
1,547
1,579
1,660
1,632
1,589
1,635
1,661
1,683
1,671
1,672
Sales/Revenue/Turnover
430
542
636
849
1,096
1,462
1,713
1,701
2,169
2,331
2,866
2,536
2,647
2,336
Operating Margin (%)
22.6
22.36
23.39
25.8
29.46
23.58
23.7
26.34
28.86
34.54
33.6
31.33
31.78
31.74
Depreciation Expense
16
23
27
45
53
56
62
66
81
87
101
121
124
- -
Net Income, GAAP
90
110
136
197
278
263
124
359
207
703
847
707
735
652
Effective Tax Rate (%)
15.12
14.16
15.09
14.43
14.42
14.48
32.44
16.73
31.08
11.54
6.67
10.86
10.3
9.79
Profit Margin (%)
20.88
20.25
21.43
23.23
25.34
18.01
7.27
21.1
9.53
30.17
29.56
27.88
27.78
27.89
Working Capital
352
278
358
110
312
322
1,060
1,165
1,295
1,235
1,478
1,608
1,755
1,785
LT Debt
- -
- -
- -
50
50
40
14
21
24
24
48
38
25
18
Total Equity
661
773
1,264
1,426
1,760
2,011
2,700
2,929
2,904
3,402
3,932
4,300
4,736
4,439
Return on Invested Capital (%)
13.56
14.35
12.28
13.27
16.59
13.28
4.54
12.19
6.78
22.96
23.11
17.19
16.44
15.12
Return on Capital (%)
14.49
15.5
13.75
14.48
16.72
13.48
5.83
13.09
7.16
21.06
22.57
16.79
15.89
14.74
Return on Common Equity (%)
14.49
15.7
13.93
15.32
18.29
14.63
5.47
13.14
7.35
23.46
24.39
17.98
16.94
15.61

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
8
78
58
LT Borrowings
- -
- -
- -
LT Finance Leases
22
20
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,671
1,671
1,671
Market Capitalization
15,788
13,115
14,385

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,510
2,242
2,341
Cash, Cash Equivalents & STI
1,593
1,390
1,324
Accounts Receivable, Net
433
402
376
Inventories
274
285
311
Total Current Liabilities
584
557
556
Payables & Accruals
- -
- -
- -
ST Debt
8
78
58
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.46%
10.28%
10.15%
Free Cash Flow
53.8%
46.37%
29.6%
Net Income, GAAP
42.18%
41.16%
4%
Sales/Revenue/Turnover
16.33%
10.15%
4.36%
Total Cash Common Dividend
27.21%
23.53%
-0.5%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
656
643
622
615
2,536
2025
629
663
- -
684
2,647
2026
542
556
554
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
0.12
0.11
0.07
0.42
2025
0.12
0.1
- -
0.11
0.44
2026
0.1
0.1
0.08
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.25
2025
0.09
0.15
- -
- -
0.25
2026
0.01
0.25
- -
- -
- -

Company Description

CEO
Jian Ping Yao
Full Time Employees
2,505
Sector
Health technology
Industry
Pharmaceuticals: major
Address
AnkeBio Building Hefei AN China 230088
IPO Date
Sep 24, 2009
Business
Anhui Anke Biotechnology (Group) Co., Ltd. Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) engages primarily in the research, development, production, and sales of biopharmaceuticals, diagnostic reagents, genetic testing products, polypeptide active pharmaceutical ingredients, modern traditional Chinese medicines, chemical synthetic drugs, functional skincare products, and nutritional supplements in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone brand for growth disorders; recombinant human interferon alpha 2b in forms including lyophilized powder, liquid injection, prefilled syringe, cream, eye drops, and suppository under the Anterferon brand for chronic hepatitis B, tumors, and leukemia; monoclonal antibody drugs such as trastuzumab injection (Anseiting or ANTRASTUIN) for breast and gastric cancers, bevacizumab for non-small cell lung cancer, and anti-PD1 therapies for advanced cancers; diagnostic kits for anti-sperm antibody (MAR), semen analysis including DNA fragmentation, acrosin, morphology, viability, and leukocyte detection, as well as hormone tests like AMH and leptin; peptide drugs including etiprate, thymopentin, thymalfasin, oxytocin, somatostatin, carbetocin, salmon calcitonin, octreotide acetate, and atosiban acetate; modern Chinese medicines such as blood-activating pain-relieving plasters, musk bone-strengthening cream, snake bile川贝 liquid, jujube seed mixture, wind oil, dog skin cream, and frostbite ointment; chemical synthetics like amoxicillin granules and capsules, cefixime granules, tenofovir fumarate tablets, and azithromycin powder; functional skincare items including hyaluronic acid essences, peptide anti-wrinkle creams, repair dressings, and soothing masks; and functional nutritionals under brands like Anke Youer featuring GABA-prebiotic composites for children's growth, sleep, and weight management. Founded in 2000 and headquartered in Hefei, Anhui province, China, within the High-Tech Development Area, the company operates subsidiaries including Anhui Anke Yuliangqing Pharmaceutical Co., Ltd. for traditional medicines and Anhui Anke Hengyi Pharmaceutical Co., Ltd. for synthetics, with sales networks spanning over 30 Chinese provinces and expanding international partnerships; it maintains GMP and ISO9001-certified facilities and participates in national projects like 863 Programs. Recent developments include receipt of NMPA clinical trial approval in July 2025 for the Class 1 innovative anti-HER2 drug AK2024 injection (BSI-128) developed with Biosion; a global strategic cooperation framework agreement with Weisheng Pharmaceutical-B in 2025 to accelerate commercialization of long-acting growth hormone in China; leading an investment in November 2025 to increase capital in Bosun J Medicine (Boshenji) and secure nationwide exclusive commercialization rights to its leading CD7-CAR-T cell therapy; launch of dual-specification Anseiting trastuzumab highlighted at the 20th Shanghai International Breast Cancer Forum in November 2025; and introduction of long-acting growth hormone Shengnuowa at reproductive medicine events in November 2025, alongside recognition as a 2024 Anhui manufacturing亩均效益 leader.